Olaparib (AZD2281, Ku-0059436)

Catalog No.S1060

Olaparib (AZD2281, Ku-0059436) Chemical Structure

Molecular Weight(MW): 434.46

Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 150 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 75 Publications

13 Customer Reviews

  •  

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 48 hours, and protein extracts were subjected to western blot analysis with the indicated antibodies.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

     

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 48 hours, and protein extracts were subjected to western blot analysis with the indicated antibodies.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  •  

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 24 (A) or 12 (B) hours, subjected to staining with propidium iodide (A) or FITC-Annexin V (B), and then analyzed by flow cytometry.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Role of PARP and BER in the synergy between PTX and GMX in A549 cells. A) Cells were pre-treated +/- 1 uM olaparib (2h) then sequentially +/- 150nM PTX (24h) then +/- GMX 12nM (48h). Cells were harvested for (left) NAD+ quantification by LC-MS/MS (mean +/-SD of quadruplicates) or (right) viability by CellTiter-Glo (mean +/-SD of duplicates) B) PAR modification of proteins and γ-H2AX levels were measured in extracts treated as in A) by western blotting.

    Cancer Res 2014 74(21), 5948-54. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  •  

    Mechanism of FK866/olaparib synergy. FK866 exacerbates levels of gH2AX caused by olaparib. CAL51 cells were exposed to FK866 and/or olaparib for 48 h and cell lysates generated and immunoblotted for total and gH2AX.

    EMBO Mol Med 2012 4, 1087-1096. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    MSH3-deficient cells are sensitive to olaparib, a PARP inhibitor, and the combination with oxaliplatin. A, clonogenic survival of HCT11635, G5 without doxycycline (DOX), and G5 cells with doxycycline, which were treated with 2 μM of oxaliplatin, 2 μM of olaparib, and the combination of these two drugs. B, clonogenic survival of HT29 cells, which were treated with 1 μM oxaliplatin, 2 μM olaparib, and the combination of these two drugs.

     

     

    J Biol Chem 2011 286, 12157-12165. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • J Exp Clin Cancer Res 2013 32(1), 95. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Logarithmic growth curves of human Burkitt lymphoma cells over 5 days with 500 nmol/l of ABT-888 and AZD-2281 in combination with 0 Gy (a), 4 Gy (b), 8 Gy (c), and 12 Gy (d) of external beam radiation. The maximal relative reduction was 65.5% of viable cells and occurred with AZD-2281 (500 nmol/l) on day 5. DMSO, dimethyl sulfoxide.

    Nucl Med Commun 2011 32, 1046-51. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • Nucl Med Commun 2011 32, 1046-51. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

     

    Number of foci detected using laser confocal microscopy and fluorescent Fluor 647 anti-H2A.X-phosphorylated (Ser139) antibody. Double-stranded breaks (red) are clearly augmented in cells incubated with 500 nmol/l of ABT-888 and 500 nmol/l of AZD-2281 compared with PBS and 1% dimethyl sulfoxide controls. Image analysis was performed using ImageJ and the ‘analyze particle’ function.

    Nucl Med Commun 2011 32, 1046–1051 . Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • Olaparib inhibited cell proliferation, and CRC cells with high XRCC2 expression had higher olaparib sensitivity. The surviving fractions of SW480 cells treated with (A) 1 mM, (B) 10 mM, and (C) 50 mM olaparib were measured using CCK-8. (D) The relation between cell viability and olaparib concentration.

    Medicine (Baltimore) 2014 93(28), e294. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    in vivo suppression of PAR formation by the PARP inhibitor AZD2281 upon induction of DNA damage Primary human lung fibroblast cells (MRC-5) were pre-treated with the indicated concentration of the PARP inhibitor AZD2281 for two hours. Oxidative DNA damage was induced by 500 µM H2O2 for 10 min and cellular PARP activity was measured by immuno-staining of poly(ADP)-ribose (PAR) (right panels). The in vivo effect of PARP inhibition was compared to cells without DNA damage induction and inhibitor (control) and H2O2-treated cells without inhibitor. Average nuclear PAR staining intensities of more than 50 cells were statistically analysed by Kruskal-Wallis and the post-hoc Dunn’s Multiple Comparison tests (left panel). Asterisks indicate highly significant (p<1%) differences to H2O2-treated cells without PARP inhibitor. Thick horizontal bars mark medians and error bars the interquartile range.

    2010 Dr. David Schrmann from University of Base. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • Effect of AZD 2281 on the viability of endometrial cancer cell line Hec50 and Ishikawa and ovarian cancer cell line SKOV3,Caov3 and PA-1 was detected by WST-1 method after 3 days treatment.

     

     

    2010 Dr. Xiangbing Meng of University of Iowa. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Description Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1.
Features A potent PARP inhibitor (currently in late stage clinical trials).
Targets
PARP2 [1]
(Cell-free assay)
PARP1 [1]
(Cell-free assay)
Tankyrase-1 [1]
(Cell-free assay)
1 nM 5 nM 1.5 μM
In vitro

Olaparib would act against BRCA1 or BRCA2 mutations. Olaparib is not sensitive to tankyrase-1 (IC50 >1 μM). Olaparib could ablate the PARP-1 activity at concentrations of 30-100 nM in SW620 cells. Olaparib is hypersensitive to BRCA1-deficient cell lines (MDA-MB-463 and HCC1937), compared with BRCA1- and BRCA2-proficient cell lines (Hs578T, MDA-MB-231, and T47D). [1] Olaparib is strongly sensitive to KB2P cells due to suppression of base excision repair by PARP inhibition, which may result in the conversion of single-strand breaks to double-strand breaks during DNA replication, thus activating BRCA2-dependent recombination pathways. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
KP3.33 M2K4cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUC0JIQ> M1yxN2lEPTB;NT63NFUhKM7:TTC= M1:5d|E5PTV7NkGz
KP6.3 M3WwcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\oOEBl NGW0SmJKSzVyPUGwMlQzQCEQvF2g NH\nUVQyQDV3OU[xNy=>
KP7.7 NGn4PXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LXWVQh\A>? M4rvUGlEPTB;NUegcm0h MWmxPFU2QTZzMx?=
KB2P3.4 NUHYeYdHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEKxN5Y1KGR? NYDGUlJ6UUN3ME2xNlQhVSB? NIn4TpgyQDV3OU[xNy=>
KB2P1.21 NY[wdWs2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrXSm41KGR? NEjITIFKSzVyPUi5NFchdk1i MXqxPFU2QTZzMx?=
U373-MG M4PjRWN6fG:2b4jpZ{BCe3OjeR?= MUOxJO69VSB? NF\i[GIzPCCq MU\JcoNz\WG|ZYOgdoFlcWG2aX;uJJNmdnOrdHn2bZR6 NHvCcGsyQDl3NEexNi=>
T98G MmnDR5l1d3SxeHnjJGF{e2G7 MorlNUDPxE1i NVP2dnhUOjRiaB?= MoDWTY5kemWjc3XzJJJi\GmjdHnvckB{\W6|aYTpeol1gQ>? M1vnOVE5QTV2N{Gy
U87-MG NHvMTWJEgXSxdH;4bYMhSXO|YYm= M3fscVEh|ryPIB?= MWqyOEBp M3zTbGlv[3KnYYPld{Bz[WSrYYTpc44he2Wwc3n0bZZqfHl? NVXicnp7OTh7NUS3NVI>
UVW MmjlR5l1d3SxeHnjJGF{e2G7 MVu1NFAhdk1? NEHwN|QzPCCq NHTQZVNKdmO{ZXHz[ZMhemGmaXH0bY9vKHOnboPpeIl3cXS7 NF7Cdo0yQDl3NEexNi=>
HeLa M4rB[WZ2dmO2aX;uJGF{e2G7 MXi1NFAhdk1? NV7ST|JqPCCq MlO1R4F2e2W|IHGgcY9l\XO2IHTlcIF6KGmwIILlbo9qdmmwZzDv[kBz[WSrYYTpc44ucW6mdXPl[EBFVkFiYoLlZYt{ M3HmUFE5QTV2N{Gy
HeLa NUHJTlM{TnWwY4Tpc44hSXO|YYm= MkfrNUDPxE1i MX:yOEBp NIjzOIRGdmijbnPld{Bz[WSrYYTpc44ucW6mdXPl[EBUNXCqYYPlJIFzemW|dB?= M3\3fFE5QTV2N{Gy
T98G NIXpOnNHfW6ldHnvckBCe3OjeR?= NYnKe3ByOSEQvF2g NF[5VYszPCCq M1rNdmVvcGGwY3XzJJJi\GmjdHnvck1qdmS3Y3XkJHMueGijc3WgZZJz\XO2 Ml\4NVg6PTR5MUK=
L3 MULDfZRwfG:6aXOgRZN{[Xl? M33TRlUh|ryPIB?= MonHPVYhcA>? NGfw[5BFVVOR NYrQT41XW2mpbnnmbYNidnSueTDpcohq[mm2czDj[YxtKHO3co\peoFt MonQNlAyOjR2NUm=
Granta-519 NGjkcphEgXSxdH;4bYMhSXO|YYm= NV\sPXdbPSEQvF2g NULhNZN1QTZiaB?= NHL1ZWtFVVOR NYTtNYprW2yrZ3j0cJkhcW6qaXLpeJMh[2WubDDzeZJ3cX[jbB?= NYDXXG1yOjBzMkS0OVk>
BT M4HDeGN6fG:2b4jpZ{BCe3OjeR?= NYP6bo9nPSEQvF2g MmS4PVYhcA>? NHTDO|RFVVOR MX3TcIlocHSueTDpcohq[mm2czDj[YxtKHO3co\peoFt MUGyNFEzPDR3OR?=
UPN2 NUfPXoZvS3m2b4TvfIlkKEG|c3H5 M1;zUVUh|ryPIB?= MXm5OkBp NUjUSohlTE2VTx?= MVLTcIlocHSueTDpcohq[mm2czDj[YxtKHO3co\peoFt NH2zW44zODF{NES1PS=>
HBL-2 M{i5SGN6fG:2b4jpZ{BCe3OjeR?= MmLNOUDPxE1i NYrMR3E5QTZiaB?= MXTEUXNQ M1TWcXNtcWeqdHz5JIlvcGmkaYTzJINmdGxic4Xyeol3[Wx? NH7xVpgzODF{NES1PS=>
JVM-2 NVrjWoRwS3m2b4TvfIlkKEG|c3H5 M2XYb|Uh|ryPIB?= MlTQPVYhcA>? M{GxbmROW09? MUnTcIlocHSueTDpcohq[mm2czDj[YxtKHO3co\peoFt M3G0W|IxOTJ2NEW5
Z138 MoW2R5l1d3SxeHnjJGF{e2G7 Mn3kOUDPxE1i MnPVPVYhcA>? MW\EUXNQ NEnoVoJUdGmpaITsfUBqdmirYnn0d{Bk\WyuIIP1dpZqfmGu MUOyNFEzPDR3OR?=
RWPE MUjJcpZie2m4ZTDBd5NigQ>? Mn\qNlUh|ryP NInIOIc1QCCq MnvZSG1UVw>? NV\pPVM1W2mpbnnmbYNidnSueTDy[YR2[2W|IFXSS{1lemm4ZX6gZ4VtdCCrbo\hd4lwdg>? NX\SW5N6OjF3N{W4OlU>
VCaP MkDlTY53[XOrdnWgRZN{[Xl? NH6zVZQzPSEQvF2= NFfIZlQ1QCCq NE[4Tm5FVVOR NWK5OoN1W2mpbnnmbYNidnSueTDy[YR2[2W|IFXSS{1lemm4ZX6gZ4VtdCCrbo\hd4lwdg>? NFThNZczOTV5NUi2OS=>
Mouse H2AX−/− ES Cells NW\KW3UyS3m2b4TvfIlkKEG|c3H5 NELh[FgzNjVizszN Mm\aNlAhcA>? M2K5cnNq\26rZnnjZY51dHliaX7obYJqfHNiY3XscEB{fXK4aY\hcC=> MlLSNlM{PTV2OEm=
Mouse ATM−/− ES Cells NH7TempEgXSxdH;4bYMhSXO|YYm= NVroSo43Oi53IN88US=> NHnJS3UzOCCq M3nzSnNq\26rZnnjZY51dHliaX7obYJqfHNiY3XscEB{fXK4aY\hcC=> M4\mR|I{OzV3NEi5
H1650 NF3JbZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jtNFIxKM7:TR?= NYXOWWRZOTR2IHi= MVjJR|UxRTF3LkS3JO69VQ>? M3f3clI{OjN7OEC5
H1650PTEN+ MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWSyNEDPxE1? NXjBUVRsOTR2IHi= NHLITYdKSzVyPUWwMlg{KM7:TR?= NYf1RVd7OjN{M{m4NFk>
PC-9 NV3vZWdxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LnUlIxKM7:TR?= NGq3WWoyPDRiaB?= NWXOUox2UUN3ME21Mlg5KM7:TR?= MWmyN|I{QThyOR?=
PC-9PTEN− MlL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rVNVIxKM7:TR?= M{XPdFE1PCCq M1O0VGlEPTB;Nj61NkDPxE1? NYTne4pKOjN{M{m4NFk>
MDA-MB-231 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfjRplTPSCmYYm= M3z5PWlEPTB;Nj65JO69VQ>? NHLzW2kzOzd4MES5Oi=>
MDA-MB-468 M3PSU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXi1JIRigQ>? M2[1TWlEPTB;NT6wJO69VQ>? NYS5NWdwOjN5NkC0PVY>
BT20 M{X6bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXq1JIRigQ>? MkexTWM2OD15Lkeg{txO NH31bVgzOzd4MES5Oi=>
HCC1143 M{DKfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWizUI1uPSCmYYm= NY\qdnR6UUN3ME2xNU4yKM7:TR?= MlW3NlM4PjB2OU[=
HCC1937 M1m3Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUO1JIRigQ>? NF7xNIhKSzVyPUGyMlYh|ryP NFXXTWgzOzd4MES5Oi=>
Hs578t NFX4WI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfmbGVqPSCmYYm= M37Cd2lEPTB;NT62JO69VQ>? MXGyN|c3ODR7Nh?=
Hs578t(si) NYPOOmlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHGZ5M2KGSjeR?= Mk\yTWM2OD15LkWg{txO MYqyN|c3ODR7Nh?=
BT474 Mk\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX[3fYNGPSCmYYm= M330[WlEPTB;MUmuPEDPxE1? MWOyN|c3ODR7Nh?=
JIMT1 Mnf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DHe|Uh\GG7 NE\6T|BKSzVyPUeuO{DPxE1? NVPEZY1ROjN5NkC0PVY>
SKBR3 NVrzR|BnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rV[FUh\GG7 M2i5N2lEPTB;MUGuNUDPxE1? M3rwdFI{PzZyNEm2
SUM159 NHrHPGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnnfYw2KGSjeR?= NFPzT|dKSzVyPUSuNkDPxE1? NFvFN2IzOzd4MES5Oi=>
CAMA1 M3y2TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDPOUBl[Xl? MXHJR|UxRTF3Lkig{txO M3foV|I{PzZyNEm2
MCF7 M1;w[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHFXVU3PSCmYYm= NEjacnhKSzVyPUWuPEDPxE1? MYOyN|c3ODR7Nh?=
T47D NVPXS2poT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXDOUBl[Xl? NVP2[ZIxUUN3ME25MlYh|ryP NFzwSVczOzd4MES5Oi=>
HCT116 M1T0Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLENVAxKM7:TR?= MXu0PEBp NV;zPHVsTE2VTx?= MYrJR|UxRTJwNTFOwG0h NIOw[2kzPDV5N{m0NS=>
SW1116 M4n0T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4f0[VExOCEQvF2= NF[zPWs1QCCq NWfwXZg5TE2VTx?= NGjs[VRKSzVyPUGwNEDPxE1? NWjpNJBbOjR3N{e5OFE>
HT29 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\GfJkyODBizszN NIDWTZM1QCCq M1flc2ROW09? NIXS[GhKSzVyPUG0Mlch|ryP NF;rTWMzPDV5N{m0NS=>
LoVo M3frbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHaNVAxKM7:TR?= NYHmT2Z[PDhiaB?= MnLOSG1UVw>? NVW4TJN[UUN3ME2xN{41KM7:TR?= NGPsdJAzPDV5N{m0NS=>
HCT-15 NGC2V|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjCXo0yODBizszN NGTkd4w1QCCq M1ftNmROW09? MYHJR|UxRTFyIN88US=> MlHkNlQ2Pzd7NEG=
SW48 M1PLNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnO2NVAxKM7:TR?= MWq0PEBp MnjYSG1UVw>? NXPCbm9oUUN3ME25MlUh|ryP NEHET2szPDV5N{m0NS=>
C-1 MkfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;TNVAxKM7:TR?= MXi0PEBp NWWxW4lqTE2VTx?= MXzJR|UxRTdwNjFOwG0> NILNZm4zPDV5N{m0NS=>
RKO M1;HRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVqxNFAh|ryP Mmr1OFghcA>? MWjEUXNQ NHr4[IxKSzVyPUWuPUDPxE1? NEXjOWszPDV5N{m0NS=>
HCT116 NETnfWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXyxNFAh|ryP MVi0PEBp NInWT2NFVVOR NV7rcJhwWG:2ZX70bYF1\XNiU16tN|gh[3m2b4TvfIlkcXS7IB?= MW[yOFU4Pzl2MR?=
SW1116 NGnNdHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXO0dJYyOTByIN88US=> Mmr2OFghcA>? NIj0V|ZFVVOR NHHIdIlRd3SnboTpZZRmeyCVTj2zPEBkgXSxdH;4bYNqfHli M17XPVI1PTd5OUSx
HT29 NHPMco9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWKxNFAh|ryP NWO4W3ZFPDhiaB?= MUXEUXNQ MVvQc5RmdnSrYYTld{BUVi1|ODDjfZRwfG:6aXPpeJkh NWj3PIVIOjR3N{e5OFE>
LoVo MorJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYW1TGlZOTByIN88US=> MWm0PEBp M1jFZWROW09? NVG5flVYWG:2ZX70bYF1\XNiU16tN|gh[3m2b4TvfIlkcXS7IB?= NVP1b40yOjR3N{e5OFE>
SW48 M4\2WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHYNVAxKM7:TR?= MVG0PEBp NYW3NYV5TE2VTx?= NGjoSVRRd3SnboTpZZRmeyCVTj2zPEBkgXSxdH;4bYNqfHli Mm\wNlQ2Pzd7NEG=
C-1 M{HQOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTndHBCOTByIN88US=> M3TtPFQ5KGh? MknVSG1UVw>? MkLxVI91\W62aXH0[ZMhW05vM{igZ5l1d3SxeHnjbZR6KA>? M3rISVI1PTd5OUSx
RKO NEXxXmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2f0clExOCEQvF2= MUK0PEBp MoCwSG1UVw>? MmnrVI91\W62aXH0[ZMhW05vM{igZ5l1d3SxeHnjbZR6KA>? MoDONlQ2Pzd7NEG=
HCT116 M175XGZ2dmO2aX;uJGF{e2G7 NYrlTZp5OTBibl2= M4Xme|EzKGh? MX3EUXNQ NVLDfmllUW6lcnXhd4V{KESQQTDkc5VjdGVvc4TyZY5lKGK{ZXHrd{BqdmS3Y3XkJIJ6KFOQLUO4 MlXLNlQ2Pzd7NEG=
HT29 Ml[ySpVv[3Srb36gRZN{[Xl? MVqxNEBvVQ>? NGPY[ZIyOiCq NE[0SHpFVVOR Mmf6TY5kemWjc3XzJGRPSSCmb4XicIUue3S{YX7kJIJz\WGtczDpcoR2[2WmIHL5JHNPNTN6 MXOyOFU4Pzl2MR?=
TE-6 MWHGeY5kfGmxbjDBd5NigQ>? MV:1JO69VSB? M{DqPVEzKGh? MX;EUXNQ NXfMT3ZPUW6mdXPld{BIOi:PIHHydoV{fA>? NFzUTZkzPDJzOUG2OC=>
TE-6 NUPWWW5HTnWwY4Tpc44hSXO|YYm= MVK1JO69VSB? NGT2ZmozPCCq NUn4OIxLTE2VTx?= MVvJcoNz\WG|ZYOgbY4h\G:3YnzlJJN1emGwZDDidoVic3NiKFTTRpMq M4mze|I1OjF7MU[0
Hep3B NGHMeolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWS0NEDPxE1i NVj3bI1tPzJiaB?= NE[4RpVFVVOR NGO1NJhUgW6ncnfpd5Rq[2GubImgbY5pcWKrdIOgZ4VtdCCpcn;3eIghf2m2aDDETG1GWQ>? NFnDXlkzPTB5Mke1Ni=>
Huh7 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmj1OFAh|ryPIB?= Moq3O|IhcA>? M4jCR2ROW09? MoXqV5lv\XKpaYP0bYNidGy7IHnubIljcXS|IHPlcIwh\3Kxd4ToJJdqfGhiRFjNSXE> MnfZNlUxPzJ5NUK=
Hep3B NUfZSWJ1TnWwY4Tpc44hSXO|YYm= NVfNOpdFPDBizszNJC=> NHTDNFEzPCCq NXzpV2l7TE2VTx?= NUTPW4lKUW6mdXPld{BTV1NicILv[JVkfGmxbjD3bZRpKESKTVXR Mn7SNlUxPzJ5NUK=
Huh7 M1HwUWZ2dmO2aX;uJGF{e2G7 NX3ZbVZuPDBizszNJC=> NYj6UGh7OjRiaB?= MXfEUXNQ NUf5WWUzUW6mdXPld{BTV1NicILv[JVkfGmxbjD3bZRpKESKTVXR NITXVWszPTB5Mke1Ni=>
Hep3B NH7EcFhHfW6ldHnvckBCe3OjeR?= MV20NEDPxE1i MmP0NlQhcA>? MXzEUXNQ NXHqZnFbUW6mdXPld{Bk\WyuIHH1eI9xcGGpeTD3bZRpKESKTVXR NXrubFhOOjVyN{K3OVI>
Huh7 NXLvPZVOTnWwY4Tpc44hSXO|YYm= M{fwUlQxKM7:TTC= MYqyOEBp MnzRSG1UVw>? MlrXTY5lfWOnczDj[YxtKGG3dH;wbIFogSC5aYToJGRJVUWT MmjCNlUxPzJ5NUK=
SGC-7901 MmjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrmWJQ{OMLizszN MXO0PEBp MnPlSG1UVw>? NEX2NIpDdG:lazDvfIFtcXCuYYTpck1qdmS3Y3XkJINmdGxiZHXheIg> Mn3ONlU4PjdyN{[=
COLO-800 MnLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTBwNESxOlQh|ryP M125SnNCVkeHUh?=
EoL-1- MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTBwNU[0OFYh|ryP NYLNdnRCW0GQR1XS
NCI-H209 M1KwTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF:w[3FKSzVyPUCuPVE2PTZizszN M3HxOnNCVkeHUh?=
ES1 M1zUNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTFwMUG0NFgh|ryP NFPkO4tUSU6JRWK=
NKM-1 M1:wcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfnTWM2OD1zLkK1N|Q4KM7:TR?= MWjTRW5ITVJ?
NTERA-S-cl-D1 NY[3NGlmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjE[lVKSzVyPUGuN|M{PDFizszN NYnOW4VxW0GQR1XS
MHH-ES-1 NXHMTodTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEO3VHBKSzVyPUGuOlIxPjdizszN M{XKWHNCVkeHUh?=
ES8 MmfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjVTWM2OD1zLkeyOFE1KM7:TR?= NYfKSIZzW0GQR1XS
NCI-H720 MkLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{GyT2lEPTB;Mj6yNFY6QSEQvF2= Ml;rV2FPT0WU
EW-3 NFjlNFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTJwMke1N|Qh|ryP NYDXWIRCW0GQR1XS
D-566MG M2nrPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnDTWM2OD1{LkS0OVY5KM7:TR?= MkPnV2FPT0WU
697 NVTCXm82T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLheWU1UUN3ME2yMlg1OTd|IN88US=> NHrjNW1USU6JRWK=
ES5 MnflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3QTWM2OD1{Lki4NVg6KM7:TR?= NF;3O3dUSU6JRWK=
COLO-684 NYK3cZZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDxfYVKSzVyPUOuOVE3QTZizszN NWS3ZVY2W0GQR1XS
ML-2 M33O[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm[2TWM2OD1|Lk[wNFU5KM7:TR?= NVPoVpF{W0GQR1XS
MC-IXC M3G2fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI[1XWVKSzVyPUOuOlM{QTNizszN NFjmd5JUSU6JRWK=
DB M{LtdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkGwTWM2OD1|Lk[1OFQ5KM7:TR?= M4SycHNCVkeHUh?=
HCC2218 M{n0bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzkcYttUUN3ME2zMlc{OTB|IN88US=> M1P6V3NCVkeHUh?=
NCI-H510A NX3INlhFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTLOIQ3UUN3ME2zMlgzPzJ2IN88US=> NX6yNFB6W0GQR1XS
NCI-H526 NGHmdHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTHRmZKSzVyPUOuPFY6PThizszN NX3lbZJwW0GQR1XS
MV-4-11 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorQTWM2OD12LkGzN|M1KM7:TR?= MYHTRW5ITVJ?
PA-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2q5V2lEPTB;ND6yOVI6KM7:TR?= M1;tWHNCVkeHUh?=
EW-22 NYD5b5ZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlT4TWM2OD12LkO1PFYh|ryP NFzoOYRUSU6JRWK=
KASUMI-1 M37veWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTRwNECxNFkh|ryP MoiwV2FPT0WU
LU-139 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTRwN{W4Nlkh|ryP Mmn3V2FPT0WU
SBC-1 M{XX[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXUTWM2OD12LkiwPVA5KM7:TR?= NHTUWFRUSU6JRWK=
H4 NIPKV49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrOR2o{UUN3ME20Mlg6PDR|IN88US=> Ml\3V2FPT0WU
EW-11 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vBd2lEPTB;NT6wPFA4OiEQvF2= NXvjfIFqW0GQR1XS
NBsusSR NEn4TFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jHXGlEPTB;NT6xNlA2PSEQvF2= NWHZNok6W0GQR1XS
RPMI-8226 M{Tnbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTVwMUWyOFQh|ryP M4n1RnNCVkeHUh?=
DEL MlnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTVwMkCwNFYh|ryP MV\TRW5ITVJ?
ES4 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M130R2lEPTB;NT61NVM5QSEQvF2= M3vSc3NCVkeHUh?=
GCT NFnWcpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofLTWM2OD13LkW2PFU3KM7:TR?= MojtV2FPT0WU
NCI-H1048 NUXMWHdFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\G[mlEPTB;NT65O|I4OyEQvF2= MW\TRW5ITVJ?
NCI-SNU-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTZwMEKyJO69VQ>? M1fNNXNCVkeHUh?=
ES7 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\FbWZCUUN3ME22MlA{PTd5IN88US=> NGi5co5USU6JRWK=
SW982 NHHEcJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTZwMEmxN|ch|ryP M136bXNCVkeHUh?=
L-363 NXzHS45DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjSeJpoUUN3ME22MlM{QTd2IN88US=> NGrWSFRUSU6JRWK=
HT-1080 MoO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnIO4Q5UUN3ME22MlQ6Pjh|IN88US=> Mmn2V2FPT0WU
HAL-01 M3\jcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTZwNUGwPUDPxE1? NWrWfGNsW0GQR1XS
NB14 NInROXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF[2ZpdKSzVyPU[uOlQxOzlizszN MWTTRW5ITVJ?
EW-13 NGryNI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmf1TWM2OD14Lke3OFI1KM7:TR?= Mn;nV2FPT0WU
NY MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\YenpKSzVyPU[uPVQ3ODVizszN MVrTRW5ITVJ?
NCI-SNU-5 NHXicnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHzUIhKSzVyPUeuNVA1OzNizszN M4TENHNCVkeHUh?=
MS-1 M2jaUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTdwMUe0PVQh|ryP Ml;3V2FPT0WU
EW-16 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrGcnBKSzVyPUeuN|E5PjFizszN MoH0V2FPT0WU
LU-65 M{XodWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moi0TWM2OD15LkS4OFE4KM7:TR?= M1TXUXNCVkeHUh?=
HGC-27 MmjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXO4d2k2UUN3ME23MlczOTd|IN88US=> NFq4XWlUSU6JRWK=
CTB-1 MlvDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1Ti[mlEPTB;Nz63OlE4PSEQvF2= MnrOV2FPT0WU
5637 MoLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnXfoVKSzVyPUeuPVI5PiEQvF2= MVnTRW5ITVJ?
U251 M4XV[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTdwOUSwNVYh|ryP NWq1[pQxW0GQR1XS
HOS NI\PdJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2roN2lEPTB;OD6yN|AxPyEQvF2= M1fMd3NCVkeHUh?=
DOHH-2 NF7Jc3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\tU2lEPTB;OD6yN|U5KM7:TR?= Mmf1V2FPT0WU
EW-1 Mo\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfwXZFKSzVyPUiuN|AxQDhizszN NI\KVYJUSU6JRWK=
BV-173 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXoO2NRUUN3ME24MlU2PTRizszN MkjCV2FPT0WU
8-MG-BA NFu1WJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRThwNki5PFgh|ryP NHXMZo9USU6JRWK=
NB69 NF3tT2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjZWGNlUUN3ME24MlcxQTJzIN88US=> NVnPUIx6W0GQR1XS
NCI-H69 NX31XWh1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nJcGlEPTB;OT65NFk3OSEQvF2= MUjTRW5ITVJ?
RS4-11 MoKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnKZ2dKSzVyPUGxMlIzODhizszN NXjOW2dCW0GQR1XS
ONS-76 NUf3SoZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXUVotKSzVyPUGxMlI6PDdizszN M2\jN3NCVkeHUh?=
SF539 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2H4[GlEPTB;MUGuOFg5QSEQvF2= MmPiV2FPT0WU
HuO-3N1 MkTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3wU3pKSzVyPUGxMlU4QTZizszN MYXTRW5ITVJ?
NCI-H1651 NVzzbFZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fofmlEPTB;MUKuN|EyPSEQvF2= MUfTRW5ITVJ?
KARPAS-45 Mk\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NID5VmtKSzVyPUGyMlM4PiEQvF2= NXftSHYyW0GQR1XS
SK-NEP-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2ntXGlEPTB;MUKuOFYxQSEQvF2= MoTjV2FPT0WU
LAMA-84 Mlj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3DblY{UUN3ME2xN{4yODl3IN88US=> NUHncWl1W0GQR1XS
NCI-H1155 M3\QbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;rTWM2OD1zMz6yPFU3KM7:TR?= NUTnRZplW0GQR1XS
CTV-1 M1;ZO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rVWGlEPTB;MUOuOFQ2KM7:TR?= M3zDfXNCVkeHUh?=
QIMR-WIL NHq3dYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLyTWM2OD1zMz63PFE1KM7:TR?= Mn\tV2FPT0WU
H9 NVXOS4RuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULhfllNUUN3ME2xN{45PDd3IN88US=> MYrTRW5ITVJ?
SK-MEL-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHwXXRKSzVyPUGzMlk{PDdizszN MmPMV2FPT0WU
HD-MY-Z MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHX3cpNKSzVyPUG0MlA3OzdizszN M{S5c3NCVkeHUh?=
TI-73 NV[1[YV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXRTWM2OD1zND6yN|U3KM7:TR?= M{P5OHNCVkeHUh?=
JVM-3 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnuwTWM2OD1zNT61O|E3KM7:TR?= MXzTRW5ITVJ?
D-247MG NILSUXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3MTWM2OD1zNT61PVMh|ryP MYjTRW5ITVJ?
VA-ES-BJ M{TO[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFf6c5BKSzVyPUG1MlYxQTdizszN MVLTRW5ITVJ?
NOS-1 MnG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLTTWM2OD1zNT62OVIzKM7:TR?= NFXKdnZUSU6JRWK=
MOLT-4 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3qxdWlEPTB;MU[uO|UzKM7:TR?= MUPTRW5ITVJ?
Mo-T MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTF5LkC4OFkh|ryP NET6eG5USU6JRWK=
NCI-H1770 NGDWUWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\VTWM2OD1zNz6xOVQ{KM7:TR?= MlzyV2FPT0WU
COLO-320-HSR MlzoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTF5LkG4Nlch|ryP MYnTRW5ITVJ?
TE-12 NFLMdmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjDNJhIUUN3ME2xO{44ODV2IN88US=> NX73[2t[W0GQR1XS
NCI-H82 M3TuXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfiTWM2OD1zNz64O|I5KM7:TR?= NUjKfI1GW0GQR1XS
NEC8 Mmf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTF6LkGzNVYh|ryP M3n3b3NCVkeHUh?=
HSC-3 NF61TnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPwUVJKSzVyPUG4Mlc1OTRizszN MULTRW5ITVJ?
NCI-H1092 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULJW2VrUUN3ME2xPE44PTl3IN88US=> M2fvV3NCVkeHUh?=
NCI-H292 NXW2Z5BlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nqPGlEPTB;MUmuNFQ5QSEQvF2= MlG1V2FPT0WU
L-428 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTF7LkW1PUDPxE1? Mnv3V2FPT0WU
LU-134-A NUXiVZBET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHoTWM2OD1zOT61O|Ih|ryP M2D6[HNCVkeHUh?=
GI-ME-N M1m5cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3nUFlnUUN3ME2xPU42PzR5IN88US=> NXXaXYc3W0GQR1XS
ALL-PO NYfIRWdLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfSSXN[UUN3ME2xPU42QTd{IN88US=> MWTTRW5ITVJ?
D-283MED Mn;5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTF7LkmxOUDPxE1? NIftUIRUSU6JRWK=
D-423MG NXrOPVFRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTF7Lkm5Olch|ryP NYfjNohzW0GQR1XS
CAKI-1 MmnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\NV2lEPTB;MkCuNlIyQSEQvF2= MV3TRW5ITVJ?
ETK-1 M2HBe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\OXZhIUUN3ME2yNE4zPjF3IN88US=> M4G3U3NCVkeHUh?=
G-402 NIe2dZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\sfWlEPTB;MkCuOVM{PCEQvF2= M2HUNnNCVkeHUh?=
HL-60 NY\lT|k6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTJzLkG2NVMh|ryP MYDTRW5ITVJ?
A2058 NYLrS5N6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTJzLkS0O|ch|ryP NHLzTZZUSU6JRWK=
CHP-212 NI\2SXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTJzLkmwOVEh|ryP M2K0N3NCVkeHUh?=
KY821 NEK5VpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTJzLkm3OUDPxE1? MmToV2FPT0WU
TYK-nu NIOyNpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rFcmlEPTB;MkKuNFY2OSEQvF2= NFm0d25USU6JRWK=
JVM-2 NGWxd|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fPcWlEPTB;MkKuNlk5OyEQvF2= NF7CepBUSU6JRWK=
KU812 M3S5Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIC3TYdKSzVyPUKyMlc{OTJizszN NYTVOVV5W0GQR1XS
MKN28 NYftT21yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2T2b2lEPTB;MkKuPVAyPSEQvF2= M2HqbHNCVkeHUh?=
ECC10 NEmxdHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mni0TWM2OD1{Mz63OFEh|ryP NGPofG1USU6JRWK=
BHT-101 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTwTWM2OD1{ND6wNFA5KM7:TR?= NU\oWpFMW0GQR1XS
DU-4475 M4\hbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnCOWZKSzVyPUK0MlM{OzdizszN NEjXc|VUSU6JRWK=
769-P M1TWbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXm0S3Z3UUN3ME2yOE45PDZ4IN88US=> NFfLZZRUSU6JRWK=
HEC-1 MmPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1S5cmlEPTB;MkWuOFQ2KM7:TR?= NIHaSY5USU6JRWK=
MOLT-13 M17NTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2G0XmlEPTB;MkWuOVM{OSEQvF2= NWnHN2xFW0GQR1XS
8505C MmXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfZZ4tKSzVyPUK2MlQ6PzdizszN MlXyV2FPT0WU
GB-1 NWW5TI5rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDmOnh7UUN3ME2yOk44OTd4IN88US=> NXjUUll{W0GQR1XS
SF126 NHPBOIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTJ4Lke2OFgh|ryP MnG4V2FPT0WU
A4-Fuk M1n3PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofCTWM2OD1{Nz6xNlcyKM7:TR?= MUPTRW5ITVJ?
OVCAR-8 NHS2eYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2eycGlEPTB;MkeuNVU{QSEQvF2= MmHNV2FPT0WU
NCI-H1304 NVvW[phrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXuTWM2OD1{Nz61OEDPxE1? NI\C[|JUSU6JRWK=
GR-ST NUiyOZpoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHP3UXRKSzVyPUK4MlA1PyEQvF2= MUfTRW5ITVJ?
G-401 MknCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTJ6LkWwPVYh|ryP NIjUblhUSU6JRWK=
LXF-289 NX\aXFU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDHdoZKSzVyPUK4MlU3PTFizszN MVnTRW5ITVJ?
DBTRG-05MG NF\FNpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DvTWlEPTB;MkiuPVIxPCEQvF2= NHnTWHNUSU6JRWK=
YKG-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPRTWM2OD1{OT64Olgh|ryP MknkV2FPT0WU
GAMG MnzoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXv1dlRoUUN3ME2yPU46QTNizszN NFvKVVRUSU6JRWK=
HCT-116 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfBTWM2OD1|MD6wOVQ5KM7:TR?= MmHlV2FPT0WU
S-117 NVrzUGVFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjMUHhKSzVyPUOxMlIzPTdizszN NELpfJBUSU6JRWK=
NCI-H1693 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHkS4FKUUN3ME2zN{43PTR{IN88US=> M4rjPHNCVkeHUh?=
A427 Ml;WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HjT2lEPTB;M{OuPVk4PiEQvF2= NFzr[YhUSU6JRWK=
HT-29 NGLWVZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIr5emdKSzVyPUO0MlYxOzJizszN MonPV2FPT0WU
P12-ICHIKAWA NEm4OW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnETJc3UUN3ME2zOE44PDlzIN88US=> NUO2T3F3W0GQR1XS
CAL-51 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGS4R3NKSzVyPUO1MlA4ODlizszN MkjEV2FPT0WU
Ramos-2G6-4C10 NU\HXVBvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;qTWM2OD1|NT6yOFI2KM7:TR?= NELaWlBUSU6JRWK=
SCH NUf1enRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDzclk5UUN3ME2zOk41OTd2IN88US=> MUHTRW5ITVJ?
SK-MEL-24 M3fMTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHqTWM2OD1|Nj65NFQ1KM7:TR?= M3KzUHNCVkeHUh?=
SW1573 M4LZcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3q5fmlEPTB;M{iuO|IyPiEQvF2= MljNV2FPT0WU
BALL-1 NESyN3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTN7LkKxNlkh|ryP MYPTRW5ITVJ?
BE-13 M4DHd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LUOGlEPTB;M{muN|I6KM7:TR?= Mmm0V2FPT0WU
GI-1 NXK5W4o{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1z2XGlEPTB;M{muPFY1PyEQvF2= NX3TbGFXW0GQR1XS
GOTO MkHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTzXIZuUUN3ME2zPU46OTN7IN88US=> NXH0epR6W0GQR1XS
A673 NV6xbmhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TxOGlEPTB;NEGuNFM1OyEQvF2= MkDIV2FPT0WU
KG-1 MlX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVeySHRxUUN3ME20N{4{QTRizszN NWTnfJRGW0GQR1XS
GP5d NIDLS29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHJTWM2OD12ND6wOlY3KM7:TR?= NX6weVJNW0GQR1XS
MFM-223 MoD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTR2LkGyNlgh|ryP NHn2bmdUSU6JRWK=
OAW-42 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTR2LkK2OFMh|ryP NHvV[3BUSU6JRWK=
C8166 NXfST|JKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfHTWM2OD12NT6wPFIzKM7:TR?= NXPCXIZLW0GQR1XS
LU-99A MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfGTWM2OD12Nj6xN|IzKM7:TR?= MWLTRW5ITVJ?
NCI-H23 M4HtNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;qXWlEPTB;NE[uNVc5PSEQvF2= M3mwWXNCVkeHUh?=
HO-1-N-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTR5LkC5PVgh|ryP NF\LS5JUSU6JRWK=
A3-KAW MnPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTR5LkGwNFch|ryP MnfJV2FPT0WU
CGTH-W-1 NH;aNm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrU[YlKSzVyPUS3MlUxPjlizszN M3H6RXNCVkeHUh?=
DJM-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHqN2E6UUN3ME20O{42PDF|IN88US=> NXL4fIQ4W0GQR1XS
A101D MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLQTWM2OD12Nz62N|U4KM7:TR?= M{j4UnNCVkeHUh?=
BB30-HNC NFix[GpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTR6LkOwO|Ih|ryP MXjTRW5ITVJ?
T98G NVrBZ4lJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTR6LkS2N|Mh|ryP MWXTRW5ITVJ?
NCI-H1573 NXrve21ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jyNGlEPTB;NEmuOFQ3OiEQvF2= M17CRXNCVkeHUh?=
MEG-01 NY[ySodJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTR7Lke0NVEh|ryP M{LVcHNCVkeHUh?=
WM-115 NEfhcVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPFTWM2OD12OT65NlIzKM7:TR?= MWTTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo Combining with temozolomide, Olaparib (10 mg/kg, p.o.) significantly suppresses tumor growth in SW620 xenografts. [1] Olaparib shows great response to Brca1-/-;p53-/- mammary tumors (50 mg/kg i.p. per day), while no responses to HR-deficient Ecad-/-;p53-/- mammary tumors. Olaparib even does not show dose-limiting toxicity in tumor-bearing mice. [3] Olaparib has been used to treat with BRCA mutated tumors, such as ovarian, breast and prostate cancers. Moreover, Olaparib shows selectively inhibition to ATM (Ataxia Telangiectasia Mutated)-deficient tumor cells, which indicates to be a potential agent for treating ATM mutant lymphoid tumors. [4]

Protocol

Kinase Assay:

[1]

+ Expand

FlashPlate assay (96-well screening assay):

To columns 1 through 10, 1 μL of Olaparib (in DMSO) is added, and 1 μL DMSO only is added to the positive (POS) and negative (NEG) control wells (columns 11 and 12, respectively) of a pretreated FlashPlate. PARP-1 is diluted 1:40 in buffer (buffer B: 10% glycerol (v/v), 25 mM HEPES, 12.5 mM MgCl2,50 mM KCl, 1 mM DTT, 0.01% NP-40 (v/v), pH 7.6) and 40 μL added to all 96 wells (final PARP-1 concentration in the assay is ~1 ng/μL). The plate is sealed and shaken at RT for 15 min. Following this, 10 μL of positive reaction mix (0.2 ng/μL of double-stranded oligonucleotide [M3/M4] DNA per well, 5 μM of NAD+ final assay concentration, and 0.075 μCi 3H-NAD+ per well) is added to the appropriate wells (columns 1-11). The negative reaction mix, lacking the DNA oligonucleotide, is added to column 12 (with the mean negative control value used as the background). The plate is resealed and shaken for a further 60 min at RT to allow the reaction to continue. Then, 50 μL of ice-cold acetic acid (30%) is added to each well to stop the reaction, and the plate is sealed and shaken for a further 60 min at RT. Tritiated signal bound to the FlashPlate is then determined in counts per minute (CPM) using the TopCount plate reader.
Cell Research:

[1]

+ Expand
  • Cell lines: Breast cancer cell lines including SW620 colon, A2780 ovarian, HCC1937, Hs578T, MDA-MB-231, MDA-MB-436, and T47D
  • Concentrations: 1-300 nM
  • Incubation Time: 7-14 days
  • Method:

    The cytotoxicity of Olaparib is measured by clonogenic assay. Olaparib is dissolved in DMSO and diluted by culture media before use. The cells are seeded in six well plates and left to attach overnight. Then Olaparib is added at various concentrations and the cells are incubated for 7-14 days. After that the surviving colonies are counted for calculating the IC50.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: Brca1-/-;p53-/- mammary tumors are generated in K14cre;Brca1F/F;p53F/F mice.
  • Formulation: 50 mg/mL stocks in DMSO with 10% 2-hydroxyl-propyl-β-cyclodextrine/PBS
  • Dosages: 50 mg/kg
  • Administration: Administered via i.p. injection at 10 μL/g of body weight
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 86 mg/mL warmed (197.94 mM)
Water 0.002 mg/mL (0.0 mM)
Ethanol slightly soluble or insoluble
In vivo Add solvents individually and in order:
4% DMSO+30% PEG 300+ddH2O
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 434.46
Formula

C24H23FN4O3

CAS No. 763113-22-0
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01758731 Active, not recruiting Squamous Cell Carcinoma of the Head and Neck University of Colorado, Denver July 9, 2012 Phase 1
NCT02484404 Recruiting Lung Cancer|Breast Cancer|Ovarian Cancer|Colorectal Cancer|Prostate Cancer|Triple Negative Breast Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) June 4, 2015 Phase 1|Phase 2
NCT02769962 Recruiting Solid Tumors|Small Cell Lung Carcinoma|Carcinoma, Non-Small-Cell Lung|Lung Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) May 3, 2016 Phase 1|Phase 2
NCT01237067 Completed Cervical Cancer|Ovarian Cancer|Breast Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer|Endometrial Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 26, 2010 Phase 1
NCT00678132 Completed Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 24, 2008 Phase 1
NCT02121990 Active, not recruiting Ovarian Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer Memorial Sloan Kettering Cancer Center|AstraZeneca|Genentech, Inc. April 21, 2014 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

Related PARP Products

Tags: buy Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436) supplier | purchase Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436) cost | Olaparib (AZD2281, Ku-0059436) manufacturer | order Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID